期刊
TRANSPLANT IMMUNOLOGY
卷 21, 期 2, 页码 65-69出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.trim.2009.03.008
关键词
Xenograft injury; Clinical transplantation; Hyperacute rejection; Complement; Coagulation; Antibody
资金
- Baltimore and Nashville VAMC's
- Maryland
- VUMC General Clinical Research Centers [M01 RR016500]
- American Association of Thoracic Surgeons
- Thoracic Surgery Foundation for Research and Education
- German Research Foundation
- American Lung Association
- NIH [RNP U01 AI066335, U01 AI066719]
- VA Merit Review
- NIH NSRRC [U42 RR018877]
- Immerge Biotherapeutics, Inc
- Genzyme, Inc
- Revivicor, Inc
The use of porcine organs for clinical transplantation is a promising potential solution to the shortage of human organs. Preformed anti-pig antibody is the primary cause of hyperacute rejection, while elicited antibody can contribute to subsequent delayed xenograft rejection. This article will review recent progress to overcome antibody mediated xenograft rejection, through modification of the host immunity and use of genetically engineered pig organs. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据